UroReviews

Highlights from ASCO GU 2026: An Intra-patient Contemporaneous Comparison of 18F-piflufolastat and 18F-flotufolastat Urinary Radioactivity and Local and Pelvic Region Detection Rates in Men with Low Prostate-specific Antigen Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy

Brian T. Helfand, MD, PhD
Feb 2026

PSMA PET agents are not interchangeable

Highlights from ASCO GU 2026: Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (capi) plus Abiraterone (abi) versus Placebo (pbo) plus Abi in Patients (pts) with PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281

Daniel J. George, MD, FASCO
Feb 2026

Targeting PTEN loss with AKT inhibition.

Highlights from ASCO GU 2026: First-in-human Assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation Results of the Phase 1 PAnTHa Study

Fred Saad, MD, FRCS, CQ, FCAHS
Feb 2026

Promising phase 1 safety and PSA responses in mCRPC.

2026 GU ASCO Discussant Review: Abstracts Covering the PEACE-3 Trial and BRCAAway Study

Evan Y. Yu, MD
Feb 2026

GU ASCO discussion of radium combinations and PARP inhibitor strategies in metastatic castration-resistant prostate cancer.

Chat with usLiveChat